bFGF

PreclinicalSmall molecule

SShanghai Dermatology Hospital

bFGF is one of 45 small molecule programs targeting Growth. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

79 competitors in Growth

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Phase 3

30 2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Phase 3

1 3

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

8 4

Piqray

Novartis

Phase 2

2 5

Acipimox

Boehringer Ingelheim

Phase 2

1 6

Lenvima

Eisai

Preclinical

1 7

Zolymbus

AbbVie

Preclinical

1 8

Zyloprim

Jazz Pharmaceuticals

Preclinical

1 9

Aricept

Eisai

Preclinical

1 10

TY-9591

TTYK Medicines, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin

Recruiting·SShanghai Dermatology Hospital·N/A·NCT06516939·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for bFGF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bFGF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bFGF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Dermatology Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Dermatology Hospital

bFGF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

References

Drug Info

Quick Facts

Related News